ZYXI:NSD-Zynex Inc (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 8.18

Change

-0.01 (-0.12)%

Market Cap

N/A

Volume

0.10M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

+1.22 (+1.71%)

USD 8.92B
PDCO Patterson Companies Inc

+0.22 (+1.01%)

USD 1.93B
AHG Akso Health Group ADR

+0.15 (+15.82%)

USD 0.22B
EDAP EDAP TMS SA

-0.07 (-2.22%)

USD 0.12B
YI 111 Inc

-0.05 (-7.69%)

USD 0.05B
COSM Cosmos Health Inc.

-0.03 (-2.63%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.89% 43% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.89% 43% F 28% F
Trailing 12 Months  
Capital Gain 1.87% 86% B+ 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.87% 86% B+ 45% F
Trailing 5 Years  
Capital Gain -18.12% 67% D+ 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.12% 67% D+ 35% F
Average Annual (5 Year Horizon)  
Capital Gain 2.13% 43% F 48% F
Dividend Return 2.13% 43% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.63% 71% C- 42% F
Risk Adjusted Return 4.89% 43% F 42% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.